Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Immunic, Inc. Common Stock

IMUX

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Last trade $7.31
Day change +$0.075 (+1.04%)
Day range $7.07 – $7.60
Volume 119,251
Market cap $115M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$114.82M
Price / earnings
—
Price / book
0.9×
Price / sales
—
EV / sales
—
EV / EBITDA
0.34×

Profitability

Earnings per share
-$7.03
Return on assets
-70.09%
Return on equity
-87.45%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.05×
Quick ratio
5.05×
Cash ratio
4.96×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$88.05M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IMUX, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$9.4M$7.61M$4.26M$5.98M$5.71M$5.29M$4.01M$4.36M
Research and development$25.93M$25.63M$19.07M$20.01M$21.37M$21.53M$21.62M$21.37M
Total operating expenses$35.33M$33.24M$23.33M$25.99M$27.08M$26.83M$25.63M$25.73M
Operating income-$35.33M-$33.24M-$23.33M-$25.99M-$27.08M-$26.83M-$25.63M-$25.73M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$34.1M-$32.59M-$19.3M-$25.58M-$26.82M-$25.47M-$25.18M-$24.37M
Income taxes$0$0$0$0$0$0$0$0
Net income-$34.1M-$32.59M-$19.3M-$25.58M-$26.82M-$25.47M-$25.18M-$24.37M
Net income attributable to common shareholders-$34.1M-$32.59M-$19.3M-$25.58M-$26.82M-$25.47M-$25.18M-$24.37M
EBITDA-$35.29M-$33.2M-$23.29M-$25.95M-$27.04M-$26.78M-$25.6M-$25.68M
Basic earnings per share-$0.80-$1.08-$0.99-$1.30-$2.03-$2.51-$2.50-$2.40
Diluted earnings per share-$0.80-$1.08-$0.99-$1.30-$2.03-$2.51-$2.50-$2.40

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

New Strong Buy Stocks for October 22nd

Zacks has added five stocks to its Strong Buy list today: Concrete Pumping Holdings (BBCP) with 11.8% earnings estimate increase, United Community Banks (UCB) with 2.1% increase, Transportadora De Gas (TGS) with 0.7% increase, Seagate Technology (STX) with 0.1% increase, and Immunic (IMUX) with 4.4% increase over the last 60 days.

GlobeNewswire Inc.

Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies

The global celiac disease market is experiencing significant growth driven by rising awareness of gluten-related disorders, improved diagnostic technologies, and expanding gluten-free product offerings. Key drivers include increased prevalence, advancements in diagnostics, and emerging pharmacological therapies. However, challenges such as high costs of gluten-free products, limited availability in developing regions, and lack of definitive cures constrain market expansion. Major pharmaceutical companies are investing heavily in R&D for novel treatments and personalized medicine approaches.

Benzinga

Immunic And 2 Other Stocks Under $2 Insiders Are Buying

The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. OPKO Health The Trade: OPKO Health, Inc. (NASDAQ: OPK) 10% owner Frost Gamma Investments Trust acquired a total of 500,000 shares an average price of ...

Benzinga

Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. SMX (Security Matters) Public Limited Company (NASDAQ: SMX) shares climbed 87.1% to $3.18 after the company announced it secured a majority stake in True Gold Consortium. PowerFleet, Inc. (NASDAQ: PWFL) gained 42% to $2.80. Powerfleet and MiX Telematics entered into a definitive agreement to form one of the largest mobile asset Internet of Things Software-as-a-Service providers in the world. SaverOne 2014 Ltd (NASDAQ: SVRE) rose 31.1% to $0.7010. Intrusion Inc. (NASDAQ: INTZ) gained 30.4% to $0.4565. Intrusion has been awarded a $5 million agreement with a large telecommunications provider to provide Intrusion Shield support for its data centers. Startek, Inc. (NYSE: SRT) gained 29.1% to $4.21 as the company agreed to be acquired by funds managed by CSP Management Limited for $4.30 per share in cash. CISO Global Inc. (NASDAQ: CISO) shares climbed 29.1% to $0.18. CISO Global said its Argo Edge Cloud Security Platform has been independently valued at $49 million. Mobilicom Limited (NASDAQ: MOB) climbed 27.1% to $1.8050, after gaining more than 11% on Monday. PGT Innovations, Inc. (NYSE: PGTI) surged 21.8% to $31.92. NanoString Technologies, Inc. (NASDAQ: NSTG) gained 20.7% to $1.4506 after the company disclosed third-quarter preliminary results and a reorganization designed to accelerate its path to profitability. Erasca, Inc. (NASDAQ: ERAS) rose 20.6% to $2.6550. Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) climbed 19% to $0.2209. MDxHealth SA (NASDAQ: MDXH) gained 18.5% to $2.82. MDxHealth reported preliminary revenues of $19.3 million for the third quarter, representing an increase of 73% year over year. Lexicon Pharmaceuticals, Inc. (NASDAQ:

Benzinga

Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday. Immunic, Inc. (NASDAQ: IMUX) shares gained 13.2% to $1.80 in pre-market trading after the company disclosed positive interim data from Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis. Tempest Therapeutics, Inc. (NASDAQ: TPST) shares rose 21.1% to $0.2785 in pre-market trading, after falling 8% on Monday. Mobilicom Limited (NASDAQ: MOB) rose 41.1% to $2.05 in pre-market trading, after gaining more than 11% on Monday. SMX (Security Matters) Public Limited Company (NASDAQ: SMX) shares climbed 18.2% to $2.01 in pre-market trading, after jumping 18% on Monday. Domaine Des Massifs and SMX recently formed a strategic collaboration to revolutionize traceability. ContraFect Corporation (NASDAQ: CFRX) rose 16.8% to $0.5277 in pre-market trading, after surging more than 12% on Monday. ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 13.8% to $3.07 in pre-market trading. ParaZero Technologies shares jumped 133% on Monday ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 27, 20261-for-10reverse split